Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Preferred Stock Liabilities (2021 - 2024)

Senti Biosciences has reported Preferred Stock Liabilities over the past 3 years, most recently at $25.1 million for Q4 2024.

  • Quarterly results put Preferred Stock Liabilities at $25.1 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $25.1 million (changed N/A YoY), and the annual figure for FY2024 was $25.1 million, changed.
  • Preferred Stock Liabilities for Q4 2024 was $25.1 million at Senti Biosciences, down from $171.8 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for SNTI hit a ceiling of $171.8 million in Q2 2021 and a floor of $25.1 million in Q4 2024.
  • Median Preferred Stock Liabilities over the past 3 years was $171.8 million (2021), compared with a mean of $134.1 million.
  • Peak annual rise in Preferred Stock Liabilities hit 86.86% in 2022, while the deepest fall reached 86.86% in 2022.
  • Senti Biosciences' Preferred Stock Liabilities stood at $171.8 million in 2021, then changed by 0.0% to $171.8 million in 2022, then tumbled by 85.39% to $25.1 million in 2024.
  • The last three reported values for Preferred Stock Liabilities were $25.1 million (Q4 2024), $171.8 million (Q1 2022), and $171.8 million (Q4 2021) per Business Quant data.